Cargando…

An MG53-IRS1-interaction disruptor ameliorates insulin resistance

Mitsugumin 53 (MG53) is an E3 ligase that induces insulin receptor substrate-1 (IRS-1) ubiquitination and degradation in skeletal muscle. We previously demonstrated that the pharmaceutical disruption of the MG53-IRS-1 interaction improves insulin sensitivity by abrogating IRS-1 ubiquitination and in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jun Sub, Lee, Hyun, Choi, Bo Woon, Ro, Seonggu, Lee, Doyoung, Na, Jeong Eun, Hong, Jeoung-Ho, Lee, Jae-Seon, Kim, Bong-Woo, Ko, Young-Gyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994830/ https://www.ncbi.nlm.nih.gov/pubmed/29884820 http://dx.doi.org/10.1038/s12276-018-0099-9

Ejemplares similares

Dual function of MG53 in membrane repair and insulin signaling
por: Tan, Tao, et al.
Publicado: (2016)

The Hidden Threat: Endocrine Disruptors and Their Impact on Insulin Resistance
por: Dagar, Mehak, et al.
Publicado: (2023)

Endocrine disruptors also function as nervous disruptors and can be renamed endocrine and nervous disruptors (ENDs)
por: Seralini, Gilles-Eric, et al.
Publicado: (2021)

Mycoplasma exploits mammalian tunneling nanotubes for cell-to-cell dissemination
por: Kim, Bong-Woo, et al.
Publicado: (2019)

Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients
por: Lee, Yonghyun, et al.
Publicado: (2020)

Everyday endocrine disruptors: challenges in investigation and interpretation
por: Lee, Jacqueline C., et al.
Publicado: (2022)

Erchen Decoction and Linguizhugan Decoction Ameliorate Hepatic Insulin Resistance by Inhibiting IRS-1Ser307 Phosphorylation In Vivo and In Vitro
por: Zhang, Huicun, et al.
Publicado: (2017)

Cardiac effects and clinical applications of MG53
por: Zhong, Weina, et al.
Publicado: (2021)

The analysis of endocrine disruptors in patients with central precocious puberty
por: Jung, Mo Kyung, et al.
Publicado: (2019)

MG53 is not a critical regulator of insulin signaling pathway in skeletal muscle
por: Philouze, Clothilde, et al.
Publicado: (2021)

Nutritional interventions to ameliorate the effect of endocrine disruptors on human reproductive health: A semi‐structured review from FIGO
por: Corbett, Gillian A., et al.
Publicado: (2022)

Space Flight-Promoted Insulin Resistance as a Possible Disruptor of Wound Healing
por: Strollo, F., et al.
Publicado: (2022)

Resveratrol metabolites ameliorate insulin resistance in HepG2 hepatocytes by modulating IRS-1/AMPK
por: Teng, Wendi, et al.
Publicado: (2018)

Endocrine Disruptors and Obesity
por: Darbre, Philippa D.
Publicado: (2017)

Vitamin D ameliorates liver pathology in mice caused by exposure to endocrine disruptor bisphenol A
por: Al-Griw, Mohamed A., et al.
Publicado: (2023)

The Relationship between Uterine Myoma Growth and the Endocrine Disruptor in Postmenopausal Women
por: Jeong, Eun Ho, et al.
Publicado: (2013)

MG53′s new identity
por: Levy, Jennifer R, et al.
Publicado: (2013)

Investigations on Potential Applications of CaMg(CO(3))(2) Nanoparticles
por: Han, Ihn, et al.
Publicado: (2022)

Impaired Insulin Signaling is Associated with Hepatic Mitochondrial Dysfunction in IR(+/−)-IRS-1(+/−) Double Heterozygous (IR-IRS1dh) Mice
por: Franko, Andras, et al.
Publicado: (2017)

Dexmedetomidine Ameliorates Sleep Deprivation-Induced Depressive Behaviors in Mice
por: Moon, Eun-Jin, et al.
Publicado: (2018)

Endocrine disruptors : effects on male and female reproductive systems /
Publicado: (2005)

Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure
por: Ballester, Maria Rosa, et al.
Publicado: (2015)

Emerging Research on Endocrine Disruptors
por: Schwartz, David A., et al.
Publicado: (2007)

National strategy on endocrine disruptors.
Publicado: (1996)

Priorities for endocrine disruptor research.
Publicado: (1997)

Endocrine disruptors and testis development.
por: Sharpe, R M, et al.
Publicado: (1998)

The state of the science on endocrine disruptors.
Publicado: (1998)

Polyethylene Terephthalate and Endocrine Disruptors
por: Vasami, Ralph
Publicado: (2010)

Fetal and Neonatal Endocrine Disruptors
por: Ünüvar, Tolga, et al.
Publicado: (2012)

State of the Science of Endocrine Disruptors
por: Birnbaum, Linda S.
Publicado: (2013)

The Effects of Nanomaterials as Endocrine Disruptors
por: Iavicoli, Ivo, et al.
Publicado: (2013)

Are all chemicals endocrine disruptors?
por: Wheeler, James R., et al.
Publicado: (2016)

Obesity as disruptor of the female fertility
por: Silvestris, Erica, et al.
Publicado: (2018)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

COVID-19 The Great Disruptor
por: Nikkhah, D.
Publicado: (2020)

Endocrine Disruptors and Prostate Cancer
por: Corti, Margherita, et al.
Publicado: (2022)

Endocrine Disruptors–‘Food’ for Thought
por: Mukherjee, Raktim, et al.
Publicado: (2021)

Environmental disruptors and testicular cancer
por: Faja, Fabiana, et al.
Publicado: (2022)

Triterpenoid Saponins from Stauntonia chinensis Ameliorate Insulin Resistance via the AMP-Activated Protein Kinase and IR/IRS-1/PI3K/Akt Pathways in Insulin-Resistant HepG2 Cells
por: Hu, Xin, et al.
Publicado: (2014)

Human endometrial cell coculture reduces the endocrine disruptor toxicity on mouse embryo development
por: Lee, Myeong-Seop, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_45cq1bvvns5e6gh1e21j88ve13